Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy.

Ni H, Chen P, Spring CM, Sayeh E, Semple JW, Lazarus AH, Hynes RO, Freedman J.

Blood. 2006 Apr 1;107(7):2976-83. Epub 2005 Nov 29.

2.

Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy.

Chen P, Li C, Lang S, Zhu G, Reheman A, Spring CM, Freedman J, Ni H.

Blood. 2010 Nov 4;116(18):3660-8. doi: 10.1182/blood-2010-05-284919. Epub 2010 Jul 20.

3.

Maternal anti-platelet β3 integrins impair angiogenesis and cause intracranial hemorrhage.

Yougbaré I, Lang S, Yang H, Chen P, Zhao X, Tai WS, Zdravic D, Vadasz B, Li C, Piran S, Marshall A, Zhu G, Tiller H, Killie MK, Boyd S, Leong-Poi H, Wen XY, Skogen B, Adamson SL, Freedman J, Ni H.

J Clin Invest. 2015 Apr;125(4):1545-56. doi: 10.1172/JCI77820. Epub 2015 Mar 16.

4.

Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model.

Tiller H, Killie MK, Chen P, Eksteen M, Husebekk A, Skogen B, Kjeldsen-Kragh J, Ni H.

Transfusion. 2012 Jul;52(7):1446-57. doi: 10.1111/j.1537-2995.2011.03480.x. Epub 2012 Jan 17.

PMID:
22251227
5.

The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies.

Li C, Piran S, Chen P, Lang S, Zarpellon A, Jin JW, Zhu G, Reheman A, van der Wal DE, Simpson EK, Ni R, Gross PL, Ware J, Ruggeri ZM, Freedman J, Ni H.

J Clin Invest. 2011 Nov;121(11):4537-47. doi: 10.1172/JCI57850. Epub 2011 Oct 24.

6.

Co-stimulation with LPS or Poly I:C markedly enhances the anti-platelet immune response and severity of fetal and neonatal alloimmune thrombocytopenia.

Li C, Chen P, Vadasz B, Ma L, Zhou H, Lang S, Freedman J, Ni H.

Thromb Haemost. 2013 Dec;110(6):1250-8. doi: 10.1160/TH13-04-0354. Epub 2013 Sep 26.

PMID:
24067944
8.

Three novel beta3 domain-deletion peptides for the sensitive and specific detection of HPA-4 and six low frequency beta3-HPA antibodies.

Stafford P, Garner SF, Huiskes E, Kaplan C, Kekomaki R, Santoso S, Tsuno NH, Watkins NA, Ouwehand WH.

J Thromb Haemost. 2008 Feb;6(2):376-83. Epub 2007 Nov 20.

9.

Severe neonatal alloimmune thrombocytopenia caused by maternal sensitization against a new low-frequency alloantigen (Domb ) located on platelet glycoprotein IIIa.

Sullivan MJ, Kuhlmann R, Peterson JA, Curtis BR.

Transfusion. 2017 Jul;57(7):1847-1848. doi: 10.1111/trf.14160. Epub 2017 May 18. No abstract available.

PMID:
28518345
10.

Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia.

Aslam R, Hu Y, Gebremeskel S, Segel GB, Speck ER, Guo L, Kim M, Ni H, Freedman J, Semple JW.

Blood. 2012 Sep 6;120(10):2127-32. doi: 10.1182/blood-2012-02-413526. Epub 2012 Jul 3.

11.

Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility.

Gaddipati S, Berkowitz RL, Lembet AA, Lapinski R, McFarland JG, Bussel JB.

Am J Obstet Gynecol. 2001 Oct;185(4):976-80.

PMID:
11641688
12.

Maternal intravenous immunoglobulin treatment does not prevent intracranial haemorrhage in fetal alloimmune thrombocytopenia.

Kroll H, Kiefel V, Giers G, Bald R, Hoch J, Hanfland P, Hansmann M, Mueller-Eckhardt C.

Transfus Med. 1994 Dec;4(4):293-6.

PMID:
7889141
13.

[Prenatal substitution therapy in fetal alloimmune thrombocytopenia].

Giers G, Hoch J, Bald R, Fischer J, Kroll H, Kiefel V, Scharf RE, Hanfland P, Hansmann M, Mueller-Eckhardt C.

Beitr Infusionsther Transfusionsmed. 1994;32:453-8. German.

PMID:
9480142
14.

A single-nucleotide polymorphism in the human ITGB3 gene is associated with the platelet-specific alloantigen Va (HPA-17bw) involved in fetal maternal alloimmune thrombocytopenia.

Stafford P, Garner SF, Rankin A, Kekomaki R, Watkins NA, Ouwehand WH.

Transfusion. 2008 Jul;48(7):1432-8. doi: 10.1111/j.1537-2995.2008.01737.x. Epub 2008 May 15.

PMID:
18484951
15.

Predicting risk severity and response of fetal neonatal alloimmune thrombocytopenia.

Salomon O, Rosenberg N.

Br J Haematol. 2013 Aug;162(3):304-12. doi: 10.1111/bjh.12372. Epub 2013 May 14. Review.

PMID:
23672281
16.

Fetal and neonatal alloimmune thrombocytopenia.

Zdravic D, Yougbare I, Vadasz B, Li C, Marshall AH, Chen P, Kjeldsen-Kragh J, Ni H.

Semin Fetal Neonatal Med. 2016 Feb;21(1):19-27. doi: 10.1016/j.siny.2015.12.004. Epub 2016 Jan 20. Review.

PMID:
26810319
17.

Direct fetal administration of immunoglobulins: another disappointing therapy in alloimmune thrombocytopenia.

Weiner E, Zosmer N, Bajoria R, Sepulveda W, Vaughan JI, Letsky EA, Fisk NM.

Fetal Diagn Ther. 1994 May-Jun;9(3):159-64.

PMID:
8060511
18.

Are maternal antiplatelet antibodies a prothrombotic condition leading to miscarriage?

Schmaier AH.

J Clin Invest. 2011 Nov;121(11):4241-3. doi: 10.1172/JCI60749. Epub 2011 Oct 24.

19.

Allogeneic platelet transfusions prevent murine T-cell-mediated immune thrombocytopenia.

Guo L, Yang L, Speck ER, Aslam R, Kim M, McKenzie CG, Lazarus AH, Ni H, Hou M, Freedman J, Semple JW.

Blood. 2014 Jan 16;123(3):422-7. doi: 10.1182/blood-2013-08-523308. Epub 2013 Nov 20.

20.

Immune thrombocytopenia in the foetus and the newborn: diagnosis and therapy.

Kaplan C.

Transfus Clin Biol. 2001 Jun;8(3):311-4. Review.

PMID:
11499984

Supplemental Content

Support Center